News
BHVN
14.32
-2.25%
-0.33
Biohaven reports new data on BHV-1530
TipRanks · 5d ago
Biohaven enters into clinical supply agreement with Regeneron
TipRanks · 5d ago
Weekly Report: what happened at BHVN last week (0713-0717)?
Weekly Report · 5d ago
Stay Bullish Despite The Rough Week: Aerospace, Finance, Biotech, And AI
Seeking Alpha · 5d ago
Biohaven: Nice Pipeline Momentum, But Its Runway Is A Risk
Seeking Alpha · 07/13 12:17
Weekly Report: what happened at BHVN last week (0706-0710)?
Weekly Report · 07/13 10:01
Biohaven Revamps Scientific Leadership to Drive Discovery
TipRanks · 07/09 21:29
Biohaven’s Bruce Car retires as chief scientific officer
TipRanks · 07/09 21:05
Weekly Report: what happened at BHVN last week (0629-0703)?
Weekly Report · 07/06 10:04
Biohaven, Quince, Iridium, EasyJet, Logitech Trending by Analysts
TipRanks · 07/04 09:01
Analysts’ Top Healthcare Picks: Heart Test Laboratories, Inc. (HSCS), Biohaven Ltd. (BHVN)
TipRanks · 07/01 13:00
Biohaven announces completion of enrollment in RISE3 trial
TipRanks · 06/30 11:35
Stock Indexes Finish Sharply Higher as Tech Soars
Barchart · 06/29 15:37
Biohaven falls -9.8%
TipRanks · 06/29 14:05
Biohaven enrolls first patient in Phase 3 trial of BHV-1300 for Graves’ disease
TipRanks · 06/29 11:35
Analysts Offer Insights on Healthcare Companies: Alnylam Pharma (ALNY), Biohaven Ltd. (BHVN) and Praxis Precision Medicines (PRAX)
TipRanks · 06/29 10:50
Biohaven downgraded to Underperform from Neutral at BofA
TipRanks · 06/29 10:20
Stock Indexes Push Higher as Megacap Tech Stocks Rally
Barchart · 06/29 10:16
Weekly Report: what happened at BHVN last week (0622-0626)?
Weekly Report · 06/29 10:00
Stock Indexes Supported by Strength in Megacap Tech Stocks
Barchart · 06/29 09:14
More
Webull provides a variety of real-time BHVN stock news. You can receive the latest news about Biohaven through multiple platforms. This information may help you make smarter investment decisions.
About BHVN
Biohaven Ltd. is a biopharmaceutical company focused on the discovery, development and commercialization of treatments in key therapeutic areas, including immunology, neuroscience, and oncology. It is advancing its portfolio of therapeutics, leveraging its drug development experience and multiple proprietary drug development platforms. Its clinical and preclinical programs include Kv7 ion channel modulation for epilepsy; Molecular Degrader of Extracellular Proteins (MoDE) and Targeted Removal of Aberrant Protein (TRAP) extracellular protein degradation for immunological diseases; and myostatin-activin pathway targeting agent for neuromuscular and metabolic diseases, including obesity. Its pipeline includes TYK2/JAK1 Inhibitor (brain-penetrant), IgG Degrader, Gd-IgA1 TRAP Degrader, Taldefgrobep Alfa, Kv7 Activator, TRPM3 Antagonist FGFR3 ADC, CD30 ADC, Trop2 ADC +/- PD1, and others. Its advanced product candidate from its glutamate receptor antagonist platform is troriluzole.